CJC-1295 + GHRP-2 Blend

Also known as: CJC/GHRP-2, Potent GH Stack, Mod GRF 1-29 + GHRP-2, CJC-1295 no DAC + GHRP-2

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2 (pralmorelin), 5 mg each; GHRP-2 raised GH and appetite in human studies, and no study has tested the pair.

Vendors in the catalog sell this as CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2, 5 mg each. Mod GRF 1-29 has no published study of its own, and its D-Ala2 substitution only extends the half-time of GHRH(1-29) to about 7 min in men (Soule 1994). GHRP-2 is a synthetic hexapeptide ghrelin-receptor agonist approved in Japan only as a single-dose diagnostic for GH deficiency (Chihara 2007); it sustained GH and IGF-1 over a 30-day infusion in older adults and increased food intake 36% in healthy men. IV GHRP-2 given with GHRH was synergistic in children (Pihoker 1995), the rationale for the pairing, but no study has tested this blend. FDA lists injectable GHRP-2 in category 2 for 503B outsourcing and CJC-1295 in the withdrawn-nomination table of its compounding safety-risk page.

Benefits

GH release (human, GHRP-2); increased food intake (human, GHRP-2 infusion); GH release by Mod GRF 1-29 inferred from related GHRH analogs; body-composition and recovery claims untested for the blend

Dosing reference

Research dose: 200 to 500 mcg of blend per injection (100 to 250 mcg of each at the 5 mg/5 mg ratio), 1 to 3x daily: vendor/community range, no published human dose of the blend or of Mod GRF 1-29
Range: 200 to 500 mcg, 1-3x daily
Reconstitution: 2 mL bacteriostatic water
Common vial sizes: 10 mg

Subcutaneous in community use, usually fasted. Human GHRP-2 doses: 1 mcg/kg or 100 mcg IV (diagnostic), 1 mcg/kg/h by continuous SC infusion for 30 days in older adults, and 0.3 to 3 mcg/kg/day SC in GH-deficient children. No human dose of Mod GRF 1-29 has been published. The 5 days on, 2 days off pattern is community convention.

Mechanism

Proposed, from component and class studies. Mod GRF 1-29 is a tetrasubstituted GHRH(1-29) analog acting on the pituitary GHRH receptor; its activity has not been measured directly. GHRP-2 activates the ghrelin receptor (GHS-R1a), raising GH within 60 min, and in swine it also raised ACTH and cortisol where ipamorelin did not (Raun 1998). GHRH-receptor and ghrelin-receptor agonists given together raise GH more than either alone, shown for IV GHRP-2 with GHRH in children (Pihoker 1995). GHRP-2's ghrelin-like action also fits the rise in food intake seen with continuous infusion (Laferrere 2005).

Evidence

Preclinical: animal or in vitro data only

D-Ala2 substitution, one of Mod GRF 1-29's four changes, raised the plasma half-time of GHRH(1-29) from 4.3 to 6.7 min in 10 normal men (Soule et al., 1994)
IV GHRP-2 1 mcg/kg in 10 children gave a predictable GH rise with a plasma half-life of 33 min (Pihoker et al., 1998)
30-day continuous SC infusion at 1 mcg/kg/h sustained pulsatile GH and raised IGF-1 in 17 older adults (Bowers et al., 2004)
SC GHRP-2 infusion increased ad libitum food intake 36% in 7 healthy men (Laferrere et al., 2005)
Human-trial status: no study has tested the blend as sold, and none has tested Mod GRF 1-29 itself. GHRP-2 is approved in Japan only as a GH-deficiency diagnostic (Chihara et al., 2007); IV GHRP-2 plus GHRH, not Mod GRF 1-29, was synergistic in children (Pihoker et al., 1995)

References

Side effects

No human safety study of the blend or of Mod GRF 1-29 has been published. A 30-day continuous GHRP-2 infusion kept safety screening tests normal in 17 older adults (Bowers 2004). GHRP-2 raised ACTH and cortisol in swine (Raun 1998) and increased hunger in men. Commonly reported by users (anecdotal): water retention, hunger, tingling in the hands and joint aches. CJC-1295 with DAC, a different product, has a half-life of 5.8 to 8.1 days, so mixing up the two forms changes exposure a great deal. Injectable and nasal GHRP-2 is in category 2 of FDA's 503B interim policy (added 2023-09-29), and CJC-1295 is in the withdrawn-nomination table for 503A, as of 2026-04-22: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. FDA cites serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.

Storage

Storage: Refrigerate 2-8°C (36-46°F)
Lyophilized: 2+ years at room temp, 3+ years refrigerated
Reconstituted: 28-30 days refrigerated

Pharmacology

Half-life: Mod GRF 1-29 not measured; D-Ala2-GHRH(1-29) ~6.7 min (human, IV). GHRP-2 ~33 min (children, IV bolus). The ~30 min figure for Mod GRF is community lore
Bioavailability: Not measured for Mod GRF 1-29. GHRP-2 raised GH after SC and intranasal dosing in humans; absolute bioavailability not reported. No data for the blend